source
- Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancerOn May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…
- Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten diseaseLatus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…